Article
Oncology
Yuanyuan Wang, Zhi Zhao, Jing Zhuang, Xinxin Wu, Zhizhong Wang, Bing Zhang, Ge Gao, Yinping Zhang, Caili Guo, Qingxin Xia
Summary: The high expression of the LC3 protein in CRC patients is associated with prognosis, and LC3, MSI status, and KRAS mutations are essential considerations in selecting adjuvant therapy for CRC. It helps to identify high-risk patients and explore more effective treatment options.
Article
Biochemistry & Molecular Biology
Chune Yu, Dan Luo, Jing Yu, Min Zhang, Xiaobo Zheng, Guangchao Xu, Jiaxin Wang, Huiling Wang, Yufei Xu, Ke Jiang, Jie Xu, Xuelei Ma, Jing Jing, Hubing Shi
Summary: The study identified GRB7-PLK1 as a crucial axis mediating RTKs, resulting in tolerance to MEK inhibitors. Therefore, PLK1 is a promising target for enhancing the clinical treatment of CRC patients with KRAS mutations by synergizing with MEK inhibitors.
Article
Surgery
Georgios A. Margonis, Thomas Boerner, Jean-Baptiste Bachet, Stefan Buettner, Roberto Moretto, Nikolaos Andreatos, Andrea Sartore-Bianchi, Jane Wang, Carsten Kamphues, Johan Gagniere, Sara Lonardi, Inger M. Loes, Doris Wagner, Andrea Spallanzani, Kazunari Sasaki, Richard Burkhart, Filippo Pietrantonio, Emmanouil Pikoulis, Timothy M. Pawlik, Stephanie Truant, Armando Orlandi, Anastasia Pikouli, Nicoletta Pella, Katharina Beyer, George Poultsides, Hendrik Seeliger, Federico N. Aucejo, Peter Kornprat, Klaus Kaczirek, Per E. Lonning, Martin E. Kreis, Christopher L. Wolfgang, Matthew J. Weiss, Chiara Cremolini, Stephane Benoist, Michael D'Angelica
Summary: This study investigated the clinical implications of BRAF-mutated colorectal liver metastases. The results showed that BRAF V600E mutation was associated with shorter overall survival but not recurrence-free survival. Patients with MSS tumors had shorter recurrence-free survival compared with those with MSI-high tumors. Resection of converted disease resulted in encouraging survival. Second hepatectomy improved outcomes for patients with recurrence.
Article
Biochemistry & Molecular Biology
Maud T. A. Strous, Ragna L. A. van der Linden, Audrey L. H. M. Gubbels, Timothy K. E. Faes, Koop Bosscha, Carolien M. Bronkhorst, Maryska L. G. Janssen-Heijnen, Adriaan P. de Bruine, F. Jeroen Vogelaar
Summary: This study investigates the value of adding molecular markers and the tumour-stroma ratio (TSR) to conventional histological tumour staging methods. The results suggest that poorly differentiated histology, high TSR, BRAF mutation, and MSI status are significant risk factors for cancer recurrence. Additionally, determining both TSR and BRAF improves the prognostication for disease free survival compared to using BRAF alone, and MSI shows additional value in the prognostication of disease free survival.
MOLECULAR MEDICINE
(2023)
Article
Oncology
Jean Descarpentrie, Marcos J. Arauzo-Bravo, Zongsheng He, Alexia Francois, Alvaro Gonzalez, Patricia Garcia-Gallastegi, Iker Badiola, Serge Evrard, Simon Pernot, John W. M. Creemers, Abdel-Majid Khatib
Summary: This study reveals that the malignant phenotype of colorectal cancer stem cells can be repressed by inhibition of the proprotein convertase Furin, leading to reduced expression of stem cell markers LGR5 and Nanog, as well as dysregulated expression of several calcium regulators. Targeting Furin may provide a potential therapeutic approach for colorectal cancer stem cells.
Article
Pharmacology & Pharmacy
Kangjia Luo, Yanni Song, Zilong Guan, Suwen Ou, Jinhua Ye, Songlin Ran, Hufei Wang, Yangbao Tao, Zijian Gong, Tianyi Ma, Yinghu Jin, Rui Huang, Feng Gao, Shan Yu
Summary: This study identified a gene score associated with KRAS mutation, which can distinguish the prognosis, molecular and immune characteristics, and response to immune and chemical therapy in colorectal cancer patients. These findings contribute to the advancement of drug design.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Medical Laboratory Technology
Chengfeng Wang, Diling Pan
Summary: This study investigated the relationship between BRAF, KRAS, and PIK3CA mutations and clinicopathologic features and prognosis of colorectal cancer patients. The results showed that the mutant patterns of BRAF, KRAS, and PIK3CA were not associated with the general and clinicopathological features of patients. However, these mutation patterns could be used as independent prognostic factors for colorectal cancer.
JOURNAL OF CLINICAL LABORATORY ANALYSIS
(2022)
Review
Oncology
Hiroyuki Takeda, Yu Sunakawa
Summary: BRAF mutations are an important poor prognostic factor in mCRC, but greater understanding of patient characteristics through genomic classification allows for more ideal treatment strategies.
FRONTIERS IN ONCOLOGY
(2021)
Review
Gastroenterology & Hepatology
Eiji Oki, Koji Ando, Hiroya Taniguchi, Takayuki Yoshino, Masaki Mori
Summary: Numerous clinical studies have been conducted on adjuvant therapy, with the combination of 5-fluorouracil and oxaliplatin established as the standard treatment for Stage III and high-risk Stage II patients. Biologics like bevacizumab and antiepidermal growth factor receptor antibodies have not shown additional survival benefits. The ultimate goal is to accurately predict the risk of recurrence in colon cancer patients and prevent recurrence.
ANNALS OF GASTROENTEROLOGICAL SURGERY
(2022)
Review
Biochemistry & Molecular Biology
Francesca Negri, Lorena Bottarelli, Gian Luigi de'Angelis, Letizia Gnetti
Summary: Mutations in KRAS are common in cancer, but direct targeting of KRAS has been challenging due to its resistance to small molecule inhibition and the design difficulties in creating specific drugs. However, covalent inhibitors of the KRASG12C variant have shown promise and could provide a therapeutic approach for KRAS-driven tumors.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Medical Laboratory Technology
Zohreh Mirzapoor . Abbasabadi, Dariush Hamedi Asl, Babak Rahmani, Rozhin Shahbadori, Sara Karami, Amir Peymani, Sara Taghizadeh, Fatemeh Samiee Rad
Summary: The limited genetic profile of colorectal cancer (CRC) patients in Iran, except for KRAS exon2 and BRAF V600F mutations, was investigated in this study. Mutations in KRAS, NRAS, BRAF, and PIK3CA were identified and their relationships with clinicopathological features of CRC were explored.
JOURNAL OF CLINICAL LABORATORY ANALYSIS
(2023)
Article
Immunology
Ziquan Sun, Guodong Li, Desi Shang, Jinning Zhang, Lianjie Ai, Ming Liu
Summary: The study identified molecular biomarkers associated with colon adenocarcinoma and established a prognostic model to predict patient survival and immune therapy response. Patients with high-risk scores had poor prognosis but were more likely to benefit from immune therapy.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Zhi-Hang Xu, Wen-Quan Wang, Liang Liu, Wen-Hui Lou
Summary: Pancreatic ductal adenocarcinoma (PDAC) is a devastating form of pancreatic cancer, with nonspecific early symptoms. Patients with wildtype KRAS gene benefit more from current treatments. Tailored therapies targeting alternative tumor mechanisms in KRAS wildtype PDAC can be based on patients' genetic characteristics.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
(2022)
Article
Oncology
Leonidas Apostolidis, Kristin Lang, Leila Sisic, Elena Busch, Aysel Ahadova, Ramona Wullenkord, Henrik Nienhueser, Adrian Billeter, Beat Mueller-Stich, Matthias Kloor, Dirk Jaeger, Georg Martin Haag
Summary: The prognosis of patients with relapse after multimodal treatment for esophagogastric cancer depends on the length of the relapse-free interval, extent of metastatic disease, and MSI status. Early relapse is associated with poorer overall survival. Systemic treatment is less effective in early relapse patients, while local therapy can prolong overall survival.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Anna Koumarianou, Anastasios Ntavatzikos, David Symeonidis, Christos Vallilas, Maria Giannakakou, Georgios Papaxoinis, Spyridon Xynogalos, Ioannis Boukovinas, Stamatina Demiri, Katerina Kampoli, Georgios Oikonomopoulos, Epaminontas Samantas, Eleni Res, Nikolaos Androulakis, Georgia Vourli, Ioannis Souglakos, Michalis Karamouzis
Summary: This retrospective study examined the clinical characteristics and efficacy of FTD/TPI in patients with metastatic colorectal cancer. The results showed that FTD/TPI is effective as a third-line treatment, regardless of mutational status and tumor sidedness, by prolonging progression-free survival and overall survival.
Article
Oncology
Leonie K. de Klerk, Ruben S. A. Goedegebuure, Nicole C. T. van Grieken, Johanna W. van Sandick, Annemieke Cats, Jurrien Stiekema, Rosa T. van der Kaaij, Arantza Farina Sarasqueta, Manon van Engeland, Maarten A. J. M. Jacobs, Roy L. J. van Wanrooij, Donald L. van der Peet, Aaron R. Thorner, Henk M. W. Verheul, Victor L. J. L. Thijssen, Adam J. Bass, Sarah Derks
Summary: This study identified candidate genetic biomarkers associated with response to neoadjuvant chemoradiotherapy in patients with localized oesophageal cancer, involving multiple genes. Some markers were associated with favorable histopathological response and shorter survival, while others were correlated with unfavorable histopathological response and prolonged survival.
MOLECULAR ONCOLOGY
(2021)
Article
Oncology
Stijn van Roessel, Eline C. Soer, Lois A. Daamen, Demi van Dalen, Arantza Farina Sarasqueta, Martijn W. J. Stommel, I. Quintus Molenaar, Hjalmar C. van Santvoort, Vincent C. J. van de Vlasakker, Ignace H. J. T. de Hingh, Jesse Groen, J. Sven D. Mieog, Jacob L. van Dam, Casper H. J. van Eijck, Geertjan van Tienhoven, Heinz-Josef Klumpen, Johanna W. Wilmink, Olivier R. Busch, Lodewijk A. A. Brosens, Bas Groot Koerkamp, Joanne Verheij, Marc G. Besselink
Summary: This study revealed a rate of 16% clinically relevant misdiagnoses in patients undergoing pancreatoduodenectomy, emphasizing the importance of accurate preoperative diagnosis in determining appropriate treatment strategies. The accuracy of preoperative diagnosis for pancreatic cancer and other periampullary cancers was found to be relatively low, with potential implications for the administration of neoadjuvant chemotherapy.
Article
Surgery
Enes Kacmaz, Arantza Farina Sarasqueta, Susanne van Eeden, Koen M. A. Dreijerink, Heinz-Josef Klumpen, Pieter J. Tanis, Els J. M. Nieveen van Dijkum, Anton F. Engelsman
Summary: This study based on Dutch nationwide data reveals an increasing incidence of small bowel neuroendocrine neoplasms (SB-NEN). Surgery plays a predominant role in all disease stages, and the use of somatostatin analogues (SSAs) has been increasing over time.
WORLD JOURNAL OF SURGERY
(2021)
Article
Medicine, General & Internal
Daan Linders, Marion Deken, Maxime van der Valk, Willemieke Tummers, Shadhvi Bhairosingh, Dennis Schaap, Gesina van Lijnschoten, Elham Zonoobi, Peter Kuppen, Cornelis van de Velde, Alexander Vahrmeijer, Arantza Farina Sarasqueta, Cornelis Sier, Denise Hilling
Summary: Rectal cancer patients with a complete response after neoadjuvant therapy show low expression of CEA and EpCAM in the primary tumor bed compared to the diagnostic biopsy and adjacent mucosa, indicating their potential as suitable targets for response evaluation.
Article
Oncology
F. J. Sherida H. Woei-A-Jin, Nir Weijl, Mark C. Burgmans, Arantza Farina Sarasqueta, J. Tom van Wezel, Martin N. J. M. Wasser, Minneke J. Coenraad, Jacobus Burggraaf, Susanne Osanto
Summary: Short-term use of dovitinib can lead to intratumoral blood flow reduction and modest antitumor responses. While these results support the use of systemic neoadjuvant strategies, poor tolerability of dovitinib indicates the need for dose adjustments in HCC patients.
Article
Oncology
Fanny Boyaval, Hans Dalebout, Rene Van Zeijl, Wenjun Wang, Arantza Farina-Sarasqueta, Guinevere S. M. Lageveen-Kammeijer, Jurjen J. Boonstra, Liam A. McDonnell, Manfred Wuhrer, Hans Morreau, Bram Heijs
Summary: This study investigates the changes in sugar molecules during the progression of colorectal cancer (CRC) and finds that these sugar signatures can clearly differentiate different stages of CRC progression, especially between pre-cancerous and cancerous tissue. The study also observes the spreading of glycosylation signatures into the tumor microenvironment.
Article
Oncology
Thomas P. Brouwer, Natasja L. de Vries, Tamim Abdelaal, Ricki T. Krog, Zheng Li, Dina Ruano, Arantza Farina, Boudewijn P. F. Lelieveldt, Hans Morreau, Bert A. Bonsing, Alexander L. Vahrmeijer, Frits Koning, Noel F. C. C. de Miranda
Summary: This study reveals an immunosuppressive landscape in PDAC tissues, with a depletion of cytotoxic T cells and an enrichment of regulatory T cells and B cells. The potential of ILC1-like cells in PDAC to act against tumors may be explored in therapeutic settings. Moreover, the immune cell composition of the PDAC microenvironment can be reflected in blood samples isolated from the portal vein.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Thomas Brouwer, Marieke Ijsselsteijn, Jan Oosting, Dina Ruano, Manon van der Ploeg, Frederike Dijk, Bert Bonsing, Arantza Farina, Hans Morreau, Alexander Vahrmeijer, Noel de Miranda
Summary: The infiltration of regulatory T cells (Tregs) in pancreatic ductal adenocarcinomas (PDAC) is associated with better overall survival of patients, independent of cytotoxic T cell infiltration and the transcriptomic profiles of their respective tumors.
Article
Oncology
Myrte Gorris, Nadine C. M. van Huijgevoort, Arantza Farina, Lodewijk A. A. Brosens, Hjalmar C. van Santvoort, Bas Groot Koerkamp, Marco J. Bruno, Marc G. Besselink, Jeanin E. van Hooft
Summary: Patients with pancreatic cancer associated with pancreatic cystic neoplasms (PCN) have better overall survival compared to those without PCN. Further prospective studies are needed to investigate the impact of these findings on treatment regimens for this specific patient group.
Article
Oncology
Floris A. Vuijk, Fleur Kleiburg, Wyanne A. Noortman, Linda Heijmen, Shirin Feshtali Shahbazi, Floris H. P. van Velden, Victor M. Baart, Shadhvi S. Bhairosingh, Bert D. Windhorst, Lukas J. A. C. Hawinkels, Petra Dibbets-Schneider, Neanke Bouwman, Stijn A. L. P. Crobach, Arantza Farina-Sarasqueta, Andreas W. K. S. Marinelli, Daniela E. Oprea-Lager, Rutger-Jan Swijnenburg, Frits Smit, Alexander L. Vahrmeijer, Lioe-Fee De Geus-Oei, Denise E. Hilling, Marije Slingerland
Summary: PSMA-targeted PET/CT imaging shows potential in detecting gastrointestinal cancers, but challenges include low tumor expression and high physiological uptake in surrounding organs/tissues. Additionally, [F-18]FDG PET/CT may be more effective in detecting colon, gastric, and pancreatic cancers compared to [F-18]DCFPyL PET/CT.
Article
Gastroenterology & Hepatology
Quisette P. Janssen, Rutger Quispel, Marc G. Besselink, Bert A. Bonsing, Marco J. Bruno, Michael Doukas, Arantza F. Sarasqueta, Marjolein Y. V. Homs, Jeanin E. van Hooft, Geertjan van Tienhoven, Marie-Louise F. van Velthuysen, Joanne Verheij, Rogier P. Voermans, Johanna W. Wilmink, Bas Groot Koerkamp, Casper H. J. van Eijck, Lydi M. J. W. van Driel
Summary: This study evaluates the performance of endoscopic tissue acquisition procedures for borderline resectable and resectable pancreatic ductal adenocarcinoma (PDAC). The results show that EUS-guided tissue acquisition had a sensitivity of over 85% for both initial and repeat procedures, meeting international standards.
Article
Surgery
Boris Janssen, Stijn van Roessel, Susan van Dieren, Onno de Boer, Volkan Adsay, Olca Basturk, Lodewijk Brosens, Fiona Campbell, Deyali Chatterjee, Angela Chou, Claudio Doglioni, Irene Esposito, Roger Feakins, Talia L. Fuchs, Noriyoshi Fukushima, Anthony J. Gill, Seung-Mo Hong, Ralph H. Hruban, Jeffrey Kaplan, Alyssa Krasinkas, Claudio Luchini, Chanjuan Shi, Aatur Singhi, Elizabeth Thompson, Marie-Louise F. Velthuysen, Marc G. Besselink, Joanne Verheij, Huamin Wang, Caroline Verbeke, Arantza Farina
Summary: The ISGPP-1 study found that it is unreliable to identify the effect of neoadjuvant therapy in resected pancreatic cancer, and the interobserver agreement for current tumour response scoring systems is suboptimal.
BRITISH JOURNAL OF SURGERY
(2022)
Article
Surgery
Jose Annelie Suurmeijer, Eline Christine Soer, Mark Pui Gien Dings, Yongsoo Kim, Marin Strijker, Bert Anne Bonsing, Lodewijk Adriaan Anton Brosens, Olivier Robert Busch, Jesse Vincent Groen, Johannes Berend Gerardus Halfwerk, Robbert Alexander Eduard Slooff, Hanneke Wilma Marlies van Laarhoven, Isaac Quintus Molenaar, George Johan Arnold Offerhaus, Johannes Morreau, Marc Jone van de Vijver, Arantza Farina Sarasqueta, Joanne Verheij, Marc Gerard Besselink, Maarten Fokke Bijlsma, Frederike Dijk
Summary: This study found that the molecular subtypes of pancreatic adenocarcinoma have prognostic value in clinical practice, particularly in the preoperative setting. However, the prognostic value of these subtypes decreases when histopathological parameters are available in the postoperative setting.
BRITISH JOURNAL OF SURGERY
(2022)
Article
Gastroenterology & Hepatology
Jesse Groen, Labrinus van Manen, Stijn van Roessel, Jacob L. van Dam, Bert A. Bonsing, Michael Doukas, Casper H. J. van Eijck, Arantza Farina Sarasqueta, Hein Putter, Alexander L. Vahrmeijer, Joanne Verheij, Marc G. Besselink, Bas Groot Koerkamp, J. Sven D. Mieog
Summary: The portal vein-superior mesenteric vein margin is the most affected margin in pancreatic cancer surgery. Venous resection does not independently affect time to recurrence and overall survival, but does have an impact on time to locoregional recurrence.
Review
Surgery
S. van Roessel, B. Janssen, E. C. Soer, A. Farina Sarasqueta, C. S. Verbeke, C. Luchini, L. A. A. Brosens, J. Verheij, M. G. Besselink
Summary: This systematic review aimed to provide an overview of tumour response scoring systems in pancreatic cancer following preoperative chemo(radio)therapy and found multiple scoring systems but a lack of comparative studies. More comparative data on interobserver variability and prognostic significance of these scoring systems are needed for establishing best practice in the field.
BRITISH JOURNAL OF SURGERY
(2021)
